SCHEMBL731199

SCHEMBL731199

CCOc1c[c]cc(-c2ccccc2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.54
ALDH1A1 P00352 2/20 0.54
RAB9A P51151 2/20 0.54
MAPK1 P28482 1/20 0.54
ADORA1 P30542 4/20 0.48
ADORA2A P29274 4/20 0.41
TSHR P16473 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ATM Q13315 1/20 0.41
KDM4E B2RXH2 3/20 0.40
SQOR Q9Y6N5 1/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 2/20 0.38
LTB4R Q15722 2/20 0.38
BTK Q06187 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL732707 0.80 MEN1 (0.53) NPC1ALDH1A1RAB9AMAPK1ADORA1
SCHEMBL2300904 0.79 RAB9A (0.57) NPC1ALDH1A1RAB9AMAPK1ADORA1
SCHEMBL732666 0.75 MAPK1 (0.54) NPC1ALDH1A1RAB9AMAPK1ADORA1
SCHEMBL732423 0.74 MEN1 (0.62) NPC1ALDH1A1RAB9AADORA1ADORA2A
SCHEMBL731107 0.72 MEN1 (0.37) NPC1ALDH1A1RAB9AMAPK1ADORA1
SCHEMBL1752793 0.71 NPC1 (0.53) NPC1ALDH1A1RAB9AMAPK1ADORA1
SCHEMBL25923478 0.70 NPC1 (0.62) NPC1ALDH1A1RAB9AMAPK1ADORA1
SCHEMBL731429 0.69 ALDH1A1 (0.42) NPC1ALDH1A1RAB9AADORA1ADORA2A
SCHEMBL8271637 0.69 NPC1 (0.58) NPC1ALDH1A1RAB9AMAPK1ADORA1
SCHEMBL29442363 0.69 LTB4R (0.62) NPC1ALDH1A1RAB9AMAPK1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 NPC1 2438/4885ALDH1A1 113/4885RAB9A 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.